Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
- Conditions
- Coronavirus
- Registration Number
- NCT04292340
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Brief Summary
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- The participants were diagnosed as COVID-19;
- Participants received anti-SARS-CoV-2 inactivated convalescent plasma
- Written the informed consent.
Exclusion Criteria
- Participants lacked detailed medical history
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1 1 day after receiving plasma transmission The SARS-CoV-2 nuclei acid was quantified using RT-PCR
Numbers of participants with different Clinical outcomes From receiving plasma transmission to 4 weeks Clinical outcomes include death, critical illness, recovery
The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3 3 days after receiving plasma transmission The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7 7 days after receiving plasma transmission
- Secondary Outcome Measures
Name Time Method Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 4 weeks after receiving plasma transmission
Trial Locations
- Locations (1)
Shanghai Public Health Clinical Center
🇨🇳Shanghai, Shanghai, China